Literature DB >> 12660480

Management of central retinal vein occlusion.

Sohan Singh Hayreh1.   

Abstract

The management of central retinal vein occlusion (CRVO) is discussed briefly. Since the prognosis, complications, visual outcome and management of nonischemic and ischemic CRVO are very different, the first essential step in the management of CRVO is to determine which type of CRVO one is dealing with. The various parameters which help to differentiate the two types reliably are described briefly. In this connection, the most important thing to remember is that the conventional, very prevalent use of a 10-disc area of retinal capillary obliteration is an invalid parameter to differentiate ischemic from nonischemic CRVO, or to predict ocular neovascularization (NV). Ocular NV is a complication of ischemic CRVO only. Relevant issues about the natural history of CRVO are summarized; the natural history of the disease must not be mistaken for a beneficial effect of treatment. Various advocated modes of treatment of CRVO and their relative merits are discussed, particularly photocoagulation, which is widely advocated. Controversies with regard to various aspects of CRVO management are examined. Finally, it is noted that apart from routine systemic and hematologic evaluations, the vast majority of patients with CRVO do not need an extensive and expensive workup. In conclusion, in spite of enthusiastic claims of success for various therapies, the reality is that we currently have practically no proven safe and effective treatment for CRVO. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2003        PMID: 12660480     DOI: 10.1159/000068980

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  22 in total

Review 1.  Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion.

Authors:  Tasanee Braithwaite; Afshan A Nanji; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  [The value of acetylsalicylic acid in retinal vein occlusion].

Authors:  B Mazinani; N Plange; P Walter
Journal:  Ophthalmologe       Date:  2010-11       Impact factor: 1.059

3.  Radial optic neurotomy in combined cilioretinal artery and central retinal vein occlusion.

Authors:  S Mennel; K Droutsas; C H Meyer; J C Schmidt; P Kroll
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

Review 4.  Neovascular glaucoma.

Authors:  Sohan Singh Hayreh
Journal:  Prog Retin Eye Res       Date:  2007-08-08       Impact factor: 21.198

Review 5.  Anti-vascular endothelial growth factor for neovascular glaucoma.

Authors:  Arathi Simha; Andrew Braganza; Lekha Abraham; Prasanna Samuel; Kristina Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2013-10-02

6.  Short-term results of endovascular surgery with tissue plasminogen activator injection for central retinal vein occlusion.

Authors:  Masaaki Ishida; Shinya Abe; Takuya Nakagawa; Atsushi Hayashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-08-12       Impact factor: 3.117

Review 7.  Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.

Authors:  Tasanee Braithwaite; Afshan A Nanji; Kristina Lindsley; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2014-05-01

8.  A prospective, randomised, multicenter trial for surgical treatment of central retinal vein occlusion: results of the Radial Optic Neurotomy for Central Vein Occlusion (ROVO) study group.

Authors:  Tina Aggermann; Simon Brunner; Ilse Krebs; Paulina Haas; Irene Womastek; Werner Brannath; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-09-08       Impact factor: 3.117

9.  Cardiovascular risk factors and outcome in patients with retinal vein occlusion.

Authors:  Mirko Di Capua; Antonio Coppola; Rosina Albisinni; Antonella Tufano; Anna Guida; Matteo Nicola Dario Di Minno; Ferdinando Cirillo; Marcello Loffredo; Anna Maria Cerbone
Journal:  J Thromb Thrombolysis       Date:  2010-07       Impact factor: 2.300

10.  Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy.

Authors:  Sohan Singh Hayreh; M Bridget Zimmerman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-11       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.